Pfizer's COVID-19 vaccine for children under five may lose FDA authorization, leading to potential supply shortages. Modern ...

A Food and Drug Administration official who stepped down less than two weeks ago is getting his job back as the agency's top ...

NIH Director Jay Bhattacharya offered an explanation for the cancellation of mRNA vaccine contracts that didn't align with ...

CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...

Centers for Disease Control and Prevention staffers are voicing frustration over Health Secretary Robert F. Kennedy Jr.’s ...

The primary efficacy was to demonstrate the vaccine efficacy against COVID-19 starting 14 days after mNEXSPIKE compared with Spikevax, Moderna's updated COVID-19 vaccine approved on Sept. 6, 2024.

Pfizer reported its mRNA vaccine was more than 90% effective in protecting against COVID-19 disease, but it’s important to understand what effectiveness means in their and Moderna’s studies.

Moderna's candidate COVID-19 vaccine is even more effective than Pfizer's, trial results show, a "light at the end of the tunnel" for the pandemic.

COVID vaccine maker Pfizer Inc. lost 0.6%, while its partner BioNTech, shed 3.8%. Moderna’s latest efficacy data hasn’t been published in a medical journal and further details weren’t released.

Moderna’s Covid Vaccine: What You Need to Know Denise Grady Published Nov. 16, 2020 Updated Nov. 30, 2020 Share full article ...

Moderna's trial of a new COVID-19 vaccine will target the virus variant that first emerged in South Africa. Other vaccine makers plan similar studies.

Moderna's COVID-19 Vaccine Shines In Clinical Trial Overall, the study identified 185 cases in the people who received a placebo shot, compared with 11 cases in people who got the active vaccine.